Table 1 Patient's baseline and demographic characteristics

From: Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension

 

All treated patients (N=344)

Aliskiren monotherapy (n=175)

Aliskiren+CCB (n=90)

Aliskiren+diuretic (n=79)

Age (years), mean (s.d.)

52.4 (9.91)

53.0 (10.35)

51.8 (8.96)

51.8 (9.98)

Age group, n (%)

 <65 years

305 (88.7)

151 (86.3)

83 (92.2)

71 (89.9)

 ⩾65 years

39 (11.3)

24 (13.7)

7 (7.8)

8 (10.1)

Sex, n (%)

 Male

255 (74.1)

113 (64.6)

79 (87.8)

63 (79.7)

 Female

89 (25.9)

62 (35.4)

11 (12.2)

16 (20.3)

Weight (kg), mean (s.d.)

70.2 (13.45)

68.0 (13.16)

73.6 (13.83)

71.4 (12.84)

Heighta (cm), mean (s.d.)

165.3 (8.47)

163.9 (8.84)

166.9 (6.99)

166.7 (8.73)

BMIa (kg/m2), mean (s.d.)

25.6 (3.61)

25.2 (3.39)

26.3 (3.90)

25.6 (3.65)

msDBP (mm Hg), mean (s.d.)

 bPretreatment baseline

99.5 (3.98)

98.4 (3.50)

100.8 (4.18)

100.2 (4.14)

 cLong-term study baseline

94.1 (9.20)

89.9 (8.47)

99.6 (7.00)

97.2 (8.49)

msSBP (mm Hg), mean (s.d.)

 Pretreatment baseline

154.5 (10.94)

152.5 (10.28)

156.1 (11.46)

157.1 (11.05)

 Long-term study baseline

148.7 (14.11)

144.4 (13.63)

153.6 (11.57)

152.7 (14.90)

  1. Abbreviations: BMI, body mass index; CCB, calcium channel blocker; msDBP, mean sitting diastolic blood pressure; msSBP, mean sitting systolic blood pressure.
  2. aHeight from the dose-finding study.14
  3. bPretreatment baseline—before core study when patients were not on antihypertensive therapy.13
  4. cLong-term study baseline—start of the present long-term study after 1 week washout period.
Back to article page